STipe Therapeutics, a company founded to exploit a novel approach to the stimulator of interferon genes (STING) Pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders, launched today with an EUR 20 million Series A financing. The round was co-led by Novo Holdings and Arix Bioscience plc who were joined by Wellington Partners Life Science V Fund and Sunstone Life Science Ventures A/S.
by eazee-designstudio
AMBOSS has secured €30 million in Series B funding led by Partech’s growth fund, with Target Global acting as a co-investor. Existing investors Cherry Ventures, Wellington Partners and Holtzbrinck Digital also participated in the new financing round. With the new funding, AMBOSS will accelerate the global rollout of its knowledge platform and further invest in its smart guidance application to improve daily clinical decision-making for both generalist and specialist doctors.
iOmx Therapeutics announced today the presentation of two posters at the Fifth International Cancer lmmunotherapy Conference (CICON 2019) which showcases the company’s proprietary, high-throughput genetic screening platform, iOTarg™. iOTarg is designed to broadly screen tumor cells for hijacked immune checkpoints, which enable targeting of the tumor´s immune resistance mechanisms.
Adrenomed announced today the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock. Adrecizumab is a first-in-class antibody targeting the vasoprotective peptide Adrenomedullin to restore and maintain vascular integrity in life-threatening conditions associated with vascular leakage, congestion and shock.
Confo Therapeutics today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Confo Therapeutics is building a portfolio of new medicines based on its proprietary Confo® technology. The technology makes use of antibody fragments or “ConfoBodiesTM” to stabilize G-protein coupled receptors (GPCRs) in their functional conformation, providing a superior starting point for drug design.
Themis announced today the closing of a Series D financing round totaling EUR 40 million (USD 44 million). The proceeds from this Series D round will be used to accelerate the company’s pivotal Phase 3 clinical trial program for its Chikungunya vaccine and to support further expansion into oncology indications using its proprietary measles vaccine vector platform. Concurrent with the financing, Dr. Walter Stockinger, Managing Partner at Hadean Ventures, will join Themis’ Supervisory Board.
